Cagrilintide
Cagrilintide is a long-acting research peptide designed to act like amylin, a natural hormone involved in appetite and fullness. Researchers are studying it for its possible influence on food intake, body weight, and metabolic health, both by itself and alongside semaglutide.
CAGRILINTIDE AT A GLANCE
WHAT IS CAGRILINTIDE?
Cagrilintide is a laboratory-designed peptide that acts similarly to amylin, a hormone naturally released by the pancreas after eating. Amylin helps the body communicate that food has been consumed and contributes to feelings of fullness.
Researchers developed cagrilintide to remain active longer than natural amylin. This allows it to be studied as a once-weekly option in clinical trials involving appetite, food intake, weight management, and related areas of metabolic health.
HOW DOES CAGRILINTIDE WORK?
Cagrilintide activates amylin receptors involved in communication between the digestive system and the brain. These signals help influence appetite, fullness, and how much food a person chooses to eat.
Its activity may also affect how quickly food leaves the stomach and how the body responds after a meal. Researchers are still examining how these effects work together and how cagrilintide differs from other medications studied for weight management.
Areas of Research
Cagrilintide research focuses largely on appetite and body-weight regulation. Clinical trials have studied the peptide alone and in combination with semaglutide.
APPETITE REGULATION
Exploring how amylin-related signals influence hunger and feelings of fullness.
FOOD INTAKE
Studying whether changes in appetite affect how much food participants consume.
WEIGHT MANAGEMENT
Examining changes in body weight during controlled clinical trials.
COMBINATION RESEARCH
Investigating cagrilintide alongside semaglutide through a combination known as CagriSema.
Research Highlights
Clinical studies have reported reductions in body weight among participants receiving cagrilintide. Researchers have also compared different amounts of the peptide to better understand its activity, tolerability, and potential role in weight management.
Cagrilintide has also been studied with semaglutide as CagriSema. Results have supported continued research into how amylin and GLP-1 pathways may work together, although cagrilintide remains investigational and ongoing studies continue to evaluate its safety and effectiveness.
WHAT IS CAGRILINTIDE MOST COMMONLY RESEARCHED FOR?
Cagrilintide is most commonly studied for its possible influence on appetite, food intake, and body weight. Researchers are examining whether its amylin-like activity can help people feel full sooner or remain satisfied longer after eating. Its development has focused primarily on people living with overweight or obesity.
HOW DOES CAGRILINTIDE FIT INTO PEPTIDE RESEARCH?
Cagrilintide is part of an expanding area of peptide research focused on hormones that help regulate hunger and metabolism. By acting like the naturally occurring hormone amylin, it gives researchers another way to study appetite beyond the GLP-1 pathway associated with medications such as semaglutide.
WHAT MAKES CAGRILINTIDE UNIQUE?
Cagrilintide was designed to provide longer-lasting amylin activity than the natural hormone can provide on its own. This makes once-weekly clinical research possible. It is also notable for being studied both independently and alongside semaglutide, allowing researchers to explore two different appetite-related pathways together.
CAN CAGRILINTIDE BE RESEARCHED ALONGSIDE OTHER PEPTIDES?
Cagrilintide is frequently studied alongside semaglutide in a combination called CagriSema. Researchers are exploring whether targeting both amylin and GLP-1 pathways produces different results than targeting either one alone. It may also be compared with other metabolic research subjects, including liraglutide, tesamorelin, and AOD-9604.
WHAT HAVE RESEARCHERS LEARNED ABOUT CAGRILINTIDE SO FAR?
Human clinical trials have found that cagrilintide can influence appetite and body weight, with gastrointestinal effects among the commonly reported concerns. Research involving CagriSema has also produced meaningful weight changes. These findings support further study but do not remove the need for continued safety and effectiveness research.
IS RESEARCH ON CAGRILINTIDE CONTINUING TODAY?
Cagrilintide remains part of an active clinical research program involving weight management, appetite, and metabolic health. Studies continue to examine it on its own and as part of CagriSema. Researchers are also investigating questions involving long-term outcomes, different populations, and how its effects compare with existing medications.